BIRMINGHAM, Ala., July 31 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its second quarter 2008 financial results will be released on Thursday, August 7, 2008. Following the release, BioCryst will host a conference call and Webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, BioCryst's Chief Executive Officer, and Stuart Grant, BioCryst's Chief Financial Officer.
The Webcast can be accessed by logging onto http://www.biocryst.com. Please connect to the Website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the Webcast. To participate in the conference call, please dial 1-800-860-2442 (United States) or 1-412-858-4600 (International). No passcode is needed for the call. The audio portion of the Webcast will be archived and available for replay for 14 days.
BioCryst Pharmaceuticals, Inc. is a leader in the use of
crystallography and structure-based drug design for the development of
novel therapeutics to treat cancer, cardiovascular diseases, autoimmune
diseases, and viral infections. The Company is advancing multiple internal
programs toward potential commercialization including forodesine HCl in
oncology, BCX-4208 in psoriasis and peramivir in seasonal and
life-threatening influenza. BioCryst is collaborating with Mundipharma for
the development and commercialization of forodesine HCl in markets across
Europe, Asia, Australia and certain neighboring countries. In January 2007,
the U.S. Department of Health and Human Services (HHS
|SOURCE BioCryst Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved